Business & Industry
BioPharma
Pharma Packaging Soars to $464B: Growth Factors Revealed
Industry analysts anticipate substantial growth in the global pharmaceutical packaging market, which is projected to reach USD 464.4 billion by 2031. This surge is supported by increasing demand for innovative packaging, reflected in a notable CAGR of 14.8% over...
BioPharma
Sustainable Pharma Packaging: Future Trends and Challenges
Pharmaceutical packing is still a hidden star when we talk about modern healthcare. Being able to keep the purity of drugs that are important in nature and in other situations is very important. Plastic has been used for this...
BioPharma
Sustainable Lab Automation : Altering Diagnostics By 2030
The Sustainable Development Goals (SDGs) included in the UN 2030 Agenda also address the environmental, social, and economic aspects of development. In this sense, the diagnostic and healthcare industries proceed to convert the SDG Global Data agenda into development...
Business & Industry
Global Lab Instrument Market Forecast to Grow by 6.3% CAGR
An analysis by BCC Research shows that the market for analytical laboratory instruments will grow at a compound annual growth rate (CAGR) of 6.3% from 2023 to 2028, rising from $60.9 billion in 2023 to $82.5 billion by 2028.
The...
Business & Industry
AI in Pharma Market Access and Commercialization: Transforming Pricing and Tender Strategies
The pharmaceutical industry is undergoing a profound transformation in how it approaches pricing decisions, market access negotiations, and tender participation through the strategic deployment of artificial intelligence technologies. AI in pharma market access represents a paradigm shift from traditional...
Business & Industry
FDA Looking to Lower Drugs Cost for All Americans
The Food and Drug Administration is looking to speed the development when it comes to biosimilars and has announced new guidelines, which would no longer want the makers of copycat biologics to indulge in human trials, therefore showing that...
Business & Industry
GSK Licences COPD Drug from Empirico for $85 Million Upfront
In just a space of 24 hours, GSK, in its second pipeline-expanding deal, has gone on to license the rights to a drug for chronic obstructive pulmonary disease – COPD from Empirico, the US biotech, for $85 million, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















